• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.

作者信息

Le Saux Olivia, You Benoît, Freyer Gilles

机构信息

Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.

Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.

出版信息

Clin Breast Cancer. 2014 Jun;14(3):e89-94. doi: 10.1016/j.clbc.2013.11.005. Epub 2013 Nov 21.

DOI:10.1016/j.clbc.2013.11.005
PMID:24424314
Abstract
摘要

相似文献

1
Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.HER2阳性转移性乳腺癌患者的抗血管生成治疗：病例系列
Clin Breast Cancer. 2014 Jun;14(3):e89-94. doi: 10.1016/j.clbc.2013.11.005. Epub 2013 Nov 21.
2
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.原发性和转移性乳腺癌中通过荧光原位杂交确定的HER-2状态比较。
Cancer. 2005 May 1;103(9):1763-9. doi: 10.1002/cncr.20987.
3
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.AVEREL：一项随机 III 期临床试验，评估贝伐珠单抗联合多西他赛和曲妥珠单抗作为 HER2 阳性局部复发性/转移性乳腺癌的一线治疗。
J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.
4
Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.单一机构中 HER2 FISH 结果不确定的乳腺癌的临床病理特征。
Am J Surg Pathol. 2013 Jan;37(1):120-7. doi: 10.1097/PAS.0b013e31826ab19d.
5
Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.抗HER2阻断治疗的持续时间可能会改善HER2阳性转移性乳腺癌患者的生存率。
J BUON. 2013 Jul-Sep;18(3):585-93.
6
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.曲妥珠单抗联合小剂量环磷酰胺和甲氨蝶呤治疗HER-2阳性转移性乳腺癌患者。
BMC Cancer. 2006 Sep 15;6:225. doi: 10.1186/1471-2407-6-225.
7
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?克服HER2靶向药物在五线治疗中的耐药性：贝伐单抗在HER2阳性乳腺癌治疗中仍有一席之地吗？
Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.
8
Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.贝伐单抗对局部复发性乳腺癌化疗及曲妥珠单抗耐药性的影响
Breast. 2009 Feb;18(1):66-8. doi: 10.1016/j.breast.2008.09.007. Epub 2008 Nov 13.
9
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.乳腺癌患者的HER2状态不会因术前化疗而被选择性改变，且在转移过程中保持稳定。
Cancer. 2002 Apr 15;94(8):2169-73. doi: 10.1002/cncr.10456.
10
Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.新辅助化疗对浸润性乳腺癌 HER2/neu 状态的影响。
Clin Breast Cancer. 2013 Feb;13(1):53-60. doi: 10.1016/j.clbc.2012.09.011. Epub 2012 Oct 26.

引用本文的文献

1
Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.用于乳腺癌治疗的细胞特异性生物标志物和靶向生物制药。
Cell Prolif. 2016 Aug;49(4):409-20. doi: 10.1111/cpr.12266. Epub 2016 Jun 16.